Visen Pharmaceuticals (2561)

Hong Kong
Currency in HKD
44.55
+0.15(+0.34%)
Closed·
2561 Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
2561 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
44.1045.40
52 wk Range
39.2569.15
Key Statistics
Edit
Bid/Ask
44.55 / 45.15
Prev. Close
44.55
Open
44.4
Day's Range
44.1-45.4
52 wk Range
39.25-69.15
Volume
31.2K
Average Volume (3m)
58.23K
1-Year Change
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2561 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
83.02
Upside
+86.34%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell

Visen Pharmaceuticals Company Profile

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People’s Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The company also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism. It has strategic collaboration agreements with Shanghai Pharmaceutical and the United Family Healthcare. The company was incorporated in 2018 and is headquartered in Suzhou, China.

Compare 2561 to Peers and Sector

Metrics to compare
2561
Peers
Sector
Relationship
P/E Ratio
−25.4x−9.3x−0.5x
PEG Ratio
−0.940.020.00
Price/Book
19.2x2.1x2.6x
Price / LTM Sales
1,664.6x6.4x3.1x
Upside (Analyst Target)
85.6%31.6%47.8%
Fair Value Upside
Unlock1.0%6.9%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 83.02
(+86.34% Upside)

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
-5.65 / --
Revenue / Forecast
-48,000.00 / --
EPS Revisions
Last 90 days

2561 Income Statement

FAQ

What Is the Visen Pharmaceuticals (2561) Stock Price Today?

The Visen Pharmaceuticals stock price today is 44.55

What Stock Exchange Does Visen Pharmaceuticals Trade On?

Visen Pharmaceuticals is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Visen Pharmaceuticals?

The stock symbol for Visen Pharmaceuticals is "2561."

What Is the Visen Pharmaceuticals Market Cap?

As of today, Visen Pharmaceuticals market cap is 5.08B.

What Is Visen Pharmaceuticals's Earnings Per Share (TTM)?

The Visen Pharmaceuticals EPS (TTM) is -1.95.

From a Technical Analysis Perspective, Is 2561 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Visen Pharmaceuticals Stock Split?

Visen Pharmaceuticals has split 0 times.

How Many Employees Does Visen Pharmaceuticals Have?

Visen Pharmaceuticals has 58 employees.

What is the current trading status of Visen Pharmaceuticals (2561)?

As of 09 July 2025, Visen Pharmaceuticals (2561) is trading at a price of 44.55, with a previous close of 44.55. The stock has fluctuated within a day range of 44.10 to 45.40, while its 52-week range spans from 39.25 to 69.15.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.